A 32-year-old Caucasian male with a past medical history of irritable bowel syndrome (IBS) came to the emergency department with severe abdominal pain, intractable nausea, and vomiting, which began a few hours before presentation. He denied fever, skin rash, sick contact, or recent travel. Home medications included oxycodone/acetaminophen as needed for pain but no prior exposure to Angiotensin-converting enzyme (ACE) inhibitors or Angiotensin receptor blockers (ARB). There was no history of smoking or recreational drug use. He reported having recurrent attacks of abdominal pain, nausea, and diarrhea that had previously been attributed to IBS. Interestingly, he stated that his father had similar episodes of abdominal pain, but in his father\'s case, these episodes were associated with swelling of his hands and feet. However, he was not sure of his father\'s final diagnosis.

Physical examination showed an afebrile, middle-aged man in severe pain. His heart rate was 120 beats per minute, and BP was 100/65 mmHg. Abdominal exam revealed no distention; normal bowel sounds but diffuse abdominal tenderness with some guarding. The rest of the physical exam was negative, and there was no facial swelling or skin rash noted.

Laboratory results, including serum amylase, lipase, Complete blood count (CBC), and urinalysis were unremarkable. A computed tomographic (CT) scan of his abdomen and pelvis with oral and intravenous contrast was performed. The CT scan showed a marked thickening of the fourth portion of the duodenum and the proximal jejunum, with no evidence of acute diverticulitis, bowel perforation, or bowel obstruction ([Figs. 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"}). Given the recurrent nature of his symptoms, as well as the positive family history and CT scan findings, a C4 level and C1 esterase inhibitor (C1-INH) protein level and function study were done. The result was consistent with type 1 hereditary angioedema (HAE). The patient was subsequently started on danazol for prophylaxis, which led to an improvement in symptoms and a prospective decrease in the frequency of attacks.

![Computed tomography showing marked wall thickening of small bowel.](JCHIMP-5-29114-g001){#F0001}

![Coronal view showing marked wall thickening of fourth duodenal portion and proximal jejunum.](JCHIMP-5-29114-g002){#F0002}

Discussion {#S0002}
==========

IBS represents one of the most common causes of abdominal pain, and it affects around 11% of the population around the world ([@CIT0001], [@CIT0002]). HAE is a rare cause of abdominal pain, and sometimes can be misdiagnosed as IBS. HAE is a rare autosomal dominant disorder with an estimated prevalence of 1 in 50,000 worldwide with no racial or sex differences, although women tend to have more severe disease ([@CIT0003], [@CIT0004]). In 1888, William Osler comprehensively described the clinical manifestation of HAE ([@CIT0005]), and in 1963, Donaldson and Evans subsequently discovered that HAE was caused by a mutation of the C1-INH gene ([@CIT0006]).

This *C1-INH* gene, *SERPING1*, is located on chromosome 11q11-q13.1 ([@CIT0004], [@CIT0007]). HAE accounts for about 75% of cases, with the remaining 20--25% of cases being sporadic ([@CIT0004], [@CIT0007]). C1-INH, a protein synthesized mainly by hepatocytes, belongs to the serine protease inhibitor family. Its deficiency or dysfunction leads to elevated levels of bradykinin, believed to account for most of the disease manifestations ([@CIT0004]).

The disease is divided into three different types, depending on the level and function of C1-INH:

Type 1 accounts for approximately 85% of patients and is characterized by decreased production of *C1-INH*, caused by deletions or insertions of single or multiple nucleotides into the *C1-INH* gene.

Type 2 accounts for about 15% of patients, with normal or elevated levels of dysfunctional C1-INH due to point mutations in SERPING1 ([@CIT0004], [@CIT0007]).

Type 3 has normal C1-INH level and function. It is further divided into HAE with normal C1-INH and FXII mutation and HAE of unknown origin (U-HAE) ([@CIT0004], [@CIT0008], [@CIT0009]).

HAE typically presents in the first or second decades of life ([@CIT0004], [@CIT0010]). The average time between the onset of symptoms and diagnosis is 8--10 years ([@CIT0003], [@CIT0008]).

The skin is the most commonly involved organ, followed by the gastrointestinal and respiratory systems ([@CIT0010]). The cutaneous presentation is characterized by non-pitting edema of the face, extremities, and genitalia. Gastrointestinal symptoms are the second most common complaints.

In one retrospective study of 221 patients with HAE by Bork et al., 93.3% of patients had recurrent abdominal symptoms ([@CIT0010]). Gastrointestinal symptoms included abdominal pain, nausea, vomiting, constipation, or diarrhea. The primary pathophysiology is edema of the stomach and bowel walls. In some cases, the fluid loss (third spacing) can lead to hypovolemic shock ([@CIT0007]). Physical exam can be positive for abdominal tenderness and ascites. Abdominal sonogram often shows mucosal thickening and free peritoneal fluid ([@CIT0011], [@CIT0012]). Abdominal symptoms may be the only presenting symptoms of HAE, and these symptoms may precede the skin manifestation by many years ([@CIT0008]).

CT scans of the abdomen show small bowel or colonic wall thickening with increased contrast enhancement, prominent mesenteric vessels, and mild to moderate ascites, which resolve after an acute attack ([@CIT0011], [@CIT0013]).

Endoscopy is relatively contraindicated when acute HAE is a possible differential because of the risk of inducing life-threatening laryngeal edema. However, endoscopic findings, if performed, have included diffuse erythema and mucosal edema, with bulging masses of gastric mucosa resembling a submucosal tumor ([@CIT0014]).

Diagnosis of HAE is often challenging if skin manifestations are absent. A positive family history can help, as was the case in our patient. If HAE is suspected, the C4 complement level can serve as a screening test due to its high sensitivity and high negative predictive value ([@CIT0009], [@CIT0015], [@CIT0016]). The C4 level is typically less than 30% of the mean normal level in untreated HAE ([@CIT0015], [@CIT0016]). If the C4 level is low, C1-INH level and function should be checked ([@CIT0016]). The three tests should be repeated in 1--3 months to minimize diagnostic error, given the low prevalence of HAE ([@CIT0009], [@CIT0015], [@CIT0016]).

The diagnosis of the third type of HAE with normal *C1-INH* function is either genetic (in the case of *FXII* mutation) or clinical (for unknown origin). *The international working group* has published the criteria to diagnose HAE of unknown origin. These criteria are:Presence of clinical symptomsOne or more family member with similar symptomsThe exclusion of familial and hereditary chronic urticaria with urticaria-associated angioedemaNormal *C1-INH* activity and protein in plasma, and no HAE-associated mutation in *FXII* gene ([@CIT0009]).The C1q level can be used to distinguish between HAE and acquired angioedema. C1q should be normal in HAE ([@CIT0017]).

Treatment of patients with HAE is aimed at decreasing morbidity and mortality. The main cause of mortality is airway obstruction due to acute laryngeal edema. There are currently three approved medications for the treatment of acute attacks: plasma-derived *C1-INH*, the bradykinin B2 receptor antagonist icatibant, and kallikrein inhibitor ecallantide. All have been shown to be safe and efficacious for the treatment of acute HAE attacks ([@CIT0008], [@CIT0018], [@CIT0019]).

Conclusion {#S0003}
==========

The diagnosis of HAE in our patient brings the diagnosis of IBS into question. IBS is a diagnosis of exclusion, and it should be considered after excluding other causes. Clinicians should keep HAE in mind in patients suspected of having IBS or in those who present with recurrent unexplained abdominal symptoms, as early diagnosis can lead to prompt treatment and relief of symptoms.
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